LFG316 + Sham + LFG316 Lower dose
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Geographic Atrophy
Conditions
Geographic Atrophy, Age-related Macular Degeneration
Trial Timeline
Jan 25, 2012 → Jun 24, 2015
NCT ID
NCT01527500About LFG316 + Sham + LFG316 Lower dose
LFG316 + Sham + LFG316 Lower dose is a phase 2 stage product being developed by Novartis for Geographic Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT01527500. Target conditions include Geographic Atrophy, Age-related Macular Degeneration.
What happened to similar drugs?
1 of 12 similar drugs in Geographic Atrophy were approved
Approved (1) Terminated (3) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01527500 | Phase 2 | Completed |
Competing Products
20 competing products in Geographic Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| avacincaptad pegol | Astellas Pharma | Phase 3 | 40 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2/3 | 38 |
| avacincaptad pegol | Astellas Pharma | Approved | 50 |
| Avacincaptad pegol (ACP) | Astellas Pharma | Pre-clinical | 33 |
| Avacincaptad Pegol + Sham | Astellas Pharma | Phase 3 | 40 |
| ABBV-6628 + SYFOVRE | AbbVie | Phase 1/2 | 39 |
| FWY003 + Placebo | Novartis | Phase 2 | 42 |
| CLG561 + LFG316 + Sham injection | Novartis | Phase 2 | 35 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| Lampalizumab | Roche | Phase 3 | 32 |
| RO7669330 + Syfovre™ + Izervay™ | Roche | Phase 1 | 36 |
| RO7303359 | Roche | Phase 1 | 29 |
| SAR446597 + Sham Comparator | Sanofi | Phase 1/2 | 39 |
| Pozelimab | Regeneron Pharmaceuticals | Phase 1 | 36 |
| IONIS-FB-Lrx + Placebo (sterline saline 0.9%) | Ionis Pharmaceuticals | Phase 2 | 24 |
| Tinlarebant + Placebo | Belite Bio | Phase 3 | 41 |
| Pegcetacoplan | Apellis Pharmaceuticals | Pre-clinical | 24 |
| APL-2 + APL-2 | Apellis Pharmaceuticals | Phase 3 | 34 |
| APL-2, Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 34 |